Latest Headlines

Latest Headlines

WHO meeting could change strain selection for flu vaccines

Health officials and experts will discuss ways to improve global surveillance of the flu and expedite the selection process for which flu strains to include in the vaccine each year.

CSL to buy back $723M of its shares

Australia's CSL, which completed its acquisition of Novartis' flu vaccines business this year, has launched a AU$1 million share buyback.

BARDA provides funding to Vaxart, U. of Cambridge for flu vaccine improvements

As part of its responsibility to prepare for public health threats, the U.S. Department of Health and Human Services' BARDA unit is seeking more effective influenza vaccines to incorporate into its pandemic strategy. Now, it's funding two projects it hopes will help the state of affairs.

Analysis: Sanofi's Fluzone High Dose for adults 65+ results in lower medical costs

Older adults don't have as robust an immune response to the flu vaccine as young people do. So Sanofi Pasteur formulated a higher-dose version of its trivalent Fluzone vaccine, which was found in an economic analysis to result in lower medical costs for older adults.

FluGen reels in $12M to fund PhI of its universal flu jab

A day after two high-profile organizations announced successful animal results for their own universal flu vaccine, Madison, WI-based FluGen announced a $12 million Series A round to fund the development of its candidate in the race.

J&J, Scripps Research Institute test 'universal' flu vaccine in mice, monkeys

The NIAID may have posted 94% efficacy in mice for its investigational "universal" flu vaccine, but The Scripps Research Institute and partner Johnson & Johnson are hot on its heels.

FluGen raises $12M round for universal flu vaccine

Madison, WI-based FluGen has raised a $12 million Series A from Venture Investors LLC, the Wisconsin Alumni Research Foundation, the State of Wisconsin Investment Board as well as existing investors led by Knox LLC. The money will fund the first human studies of REDEE FLU, a universal flu vaccine candidate.

CSL reports record $1.4B profit following Novartis flu vaccine purchase

CSL is now the second largest flu vaccine manufacturer in the world, thanks to its acquisition of Novartis' flu vaccine business. The company reported a AU$1.9 billion ($1.4 billion) full-year profit, a 6% increase over the previous year.

Novavax reports PhII success for quadrivalent seasonal flu vax

Novavax is making waves in the influenza space, reporting positive Phase II results for its quadrivalent seasonal flu vaccine on Thursday.

NIAID scientists one step closer to 'universal' flu vaccine

A vaccine against a wide range of flu viruses has long eluded scientists, but NIAID researchers have discovered what could be the foundation of a 'universal' flu vaccine.